KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who the competition is and how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

  • Where is my product positioned versus competitors’ products in the treatment journey?
  • What are physicians’ most frequent treatment sequences—who is benefiting and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • Where are the untapped business opportunities on which I can capitalize?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the patient journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. medical oncologists

Table of contents

  • Ovarian Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
    • Treatment Sequencing Ovarian Cancer US April 2019

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.


Related Reports

Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

View Details

Ovarian Cancer | Disease Landscape and Forecast | G7 | 2020

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inh...

View Details

Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncolo...

View Details

Ovarian Cancer - Epidemiology - Mature Markets

DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

View Details